Comparative Pharmacology
Head-to-head clinical analysis: FLOLAN versus REMODULIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOLAN versus REMODULIN.
FLOLAN vs REMODULIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epoprostenol is a prostaglandin I2 (prostacyclin) analogue that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and has antiproliferative effects on vascular smooth muscle.
Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.
Initial: 4 ng/kg/min via continuous IV infusion, then titrated in increments of 1-2 ng/kg/min at intervals of at least 15 minutes based on clinical response. Typical maintenance dose: 20-40 ng/kg/min; range: 10-80 ng/kg/min.
Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.
None Documented
None Documented
3–5 minutes (terminal elimination half-life; rapid inactivation necessitates continuous IV infusion).
Terminal elimination half-life is approximately 4 hours (range 2-7 hours) following continuous subcutaneous infusion; clinical context: requires continuous infusion due to short half-life.
Renal: 70% (as inactive metabolites); biliary/fecal: negligible.
Renal: 20-30% as unchanged drug; fecal: 70-80% as metabolites (via biliary elimination).
Category C
Category C
Prostacyclin Vasodilator
Prostacyclin Vasodilator